vs
Enact Holdings, Inc.（ACT）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Bio-Techne的1.1倍（$312.7M vs $295.9M），Enact Holdings, Inc.同比增速更快（3.6% vs -6.4%），过去两年Bio-Techne的营收复合增速更高（4.2% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
ACT vs TECH — 直观对比
营收规模更大
ACT
是对方的1.1倍
$295.9M
营收增速更快
ACT
高出10.0%
-6.4%
两年增速更快
TECH
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $295.9M |
| 净利润 | — | $38.0M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 71.3% | 18.4% |
| 净利率 | — | 12.8% |
| 营收同比 | 3.6% | -6.4% |
| 净利润同比 | — | 68.3% |
| 每股收益（稀释后） | $1.23 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTTECH
| Q4 25 | $312.7M | $295.9M | ||
| Q3 25 | $311.5M | — | ||
| Q2 25 | $304.9M | $317.0M | ||
| Q1 25 | $306.8M | $316.2M | ||
| Q4 24 | $301.8M | $297.0M | ||
| Q3 24 | $309.6M | $289.5M | ||
| Q2 24 | $298.8M | $306.1M | ||
| Q1 24 | $291.6M | $303.4M |
净利润ACTTECH
| Q4 25 | — | $38.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $33.6M | ||
| Q2 24 | — | $40.6M | ||
| Q1 24 | — | $49.1M |
毛利率ACTTECH
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
营业利润率ACTTECH
| Q4 25 | 71.3% | 18.4% | ||
| Q3 25 | 67.4% | — | ||
| Q2 25 | 70.4% | -7.5% | ||
| Q1 25 | 68.9% | 12.2% | ||
| Q4 24 | 68.9% | 16.0% | ||
| Q3 24 | 74.1% | 13.8% | ||
| Q2 24 | 78.6% | 15.0% | ||
| Q1 24 | 70.6% | 22.1% |
净利率ACTTECH
| Q4 25 | — | 12.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | 16.2% |
每股收益（稀释后）ACTTECH
| Q4 25 | $1.23 | $0.24 | ||
| Q3 25 | $1.10 | — | ||
| Q2 25 | $1.11 | $-0.11 | ||
| Q1 25 | $1.08 | $0.14 | ||
| Q4 24 | $1.05 | $0.22 | ||
| Q3 24 | $1.15 | $0.21 | ||
| Q2 24 | $1.16 | $0.26 | ||
| Q1 24 | $1.01 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $172.9M |
| 总债务越低越好 | $744.5M | $260.0M |
| 股东权益账面价值 | $5.4B | $2.0B |
| 总资产 | $6.9B | $2.5B |
| 负债/权益比越低杠杆越低 | 0.14× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ACTTECH
| Q4 25 | $582.5M | $172.9M | ||
| Q3 25 | $545.6M | — | ||
| Q2 25 | $616.0M | $162.2M | ||
| Q1 25 | $639.0M | $140.7M | ||
| Q4 24 | $602.8M | $177.5M | ||
| Q3 24 | $674.9M | $187.5M | ||
| Q2 24 | $711.3M | $152.9M | ||
| Q1 24 | $624.3M | $145.3M |
总债务ACTTECH
| Q4 25 | $744.5M | $260.0M | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | $346.0M | ||
| Q1 25 | $743.4M | $330.0M | ||
| Q4 24 | $743.0M | $300.0M | ||
| Q3 24 | $742.7M | $300.0M | ||
| Q2 24 | $742.4M | $319.0M | ||
| Q1 24 | $746.1M | $389.0M |
股东权益ACTTECH
| Q4 25 | $5.4B | $2.0B | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $5.2B | $1.9B | ||
| Q1 25 | $5.1B | $2.0B | ||
| Q4 24 | $5.0B | $2.1B | ||
| Q3 24 | $5.0B | $2.1B | ||
| Q2 24 | $4.8B | $2.1B | ||
| Q1 24 | $4.7B | $2.0B |
总资产ACTTECH
| Q4 25 | $6.9B | $2.5B | ||
| Q3 25 | $6.9B | — | ||
| Q2 25 | $6.8B | $2.6B | ||
| Q1 25 | $6.7B | $2.6B | ||
| Q4 24 | $6.5B | $2.7B | ||
| Q3 24 | $6.6B | $2.7B | ||
| Q2 24 | $6.3B | $2.7B | ||
| Q1 24 | $6.3B | $2.7B |
负债/权益比ACTTECH
| Q4 25 | 0.14× | 0.13× | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | 0.18× | ||
| Q1 25 | 0.15× | 0.16× | ||
| Q4 24 | 0.15× | 0.14× | ||
| Q3 24 | 0.15× | 0.14× | ||
| Q2 24 | 0.15× | 0.15× | ||
| Q1 24 | 0.16× | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACTTECH
| Q4 25 | $724.5M | — | ||
| Q3 25 | $192.0M | — | ||
| Q2 25 | $119.5M | $98.2M | ||
| Q1 25 | $226.7M | $41.1M | ||
| Q4 24 | $686.3M | $84.3M | ||
| Q3 24 | $188.1M | $63.9M | ||
| Q2 24 | $144.7M | $75.5M | ||
| Q1 24 | $187.3M | $81.0M |
自由现金流ACTTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
自由现金流率ACTTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
资本支出强度ACTTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
现金转化率ACTTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
